Skip to main content
Premium Trial:

Request an Annual Quote

Morewood Licenses High-Throughput Technology from Harvard

NEW YORK, Feb. 11 - Morewood Molecular Sciences has licensed high-throughput technology from Harvard University that the company hopes will "leverage" its own technology for ultra-fast enzymatics.

The license, which covers a method of high-throughput screening of certain undisclosed molecules, may "enhances Morewood's foundation technology for some applications, for ultra high throughput assaying of enzyme activity, and for point-of-care diagnostics," the company said on Monday. In return, Harvard agreed to acquire an equity interest in the firm.

 

Financial details of the non-exclusive agreement were not disclosed.
 
Morewood, a spin-off of Pittsburgh-based LaunchCyte, is a private company that develops technologies for assaying enzyme activities, including in-vitro diagnostics. It also provides ultra high-throughput screening of drug candidates. Morewood has offices in Pittsburgh and Philadelphia.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more